



Date: 13/09/2023

BSE Limited Phiroze Jeejeebhoy Towers Dalal Street Mumbai – 400 001 Script Code : 539872	National Stock Exchange of India Limited 5 th Floor, Exchange Plaza, Bandra Kurla Complex Bandra (East) Mumbai-400051 Script Code : BAJAJHCARE
--	---

Dear Sir,

Sub : Business Updates- Receipt of the Establishment Inspection Report (EIR) from the United State Food and Drug Administration (USFDA), for the Pre-approval inspection that was carried out by the USFDA in November, 2022.

In terms of regulation 30 of SEBI (LODR) Regulations, 2015, please find attached herewith business updates - Receipt of the Establishment Inspection Report (EIR) from the United State Food and Drug Administration (USFDA), for the Pre-approval inspection that was carried out by the USFDA in November, 2022 at our API manufacturing facility in Savli, Vadodara, Gujarat.

Kindly take the same on record.

Thanking you,

**For and on behalf of Board of Directors of
Bajaj Healthcare Limited**

**Aakash Keshari
Company Secretary**

Encl: a/a

BAJAJ HEALTHCARE LIMITED

Registered Office: 602-606, Bhoomi Velocity Infotech Park, Plot No: B-39, B-39A, B-39A/1, Road No. 23, Wagle Ind. Estate, Thane (West), Thane - 400604

Tel. : + 91 22 66177400/ 401; Fax : +91 22 66177458; E-mail : bajajhealth@bajajhealth.com

CIN No. L99999MH1993PLC072892



CIN: L99999MH1993PLC072892

Registered Office: 602-606, Bhoomi Velocity Infotech Park, Plot No. B-39, B-39A, B-39 A/1, Rd No.23, Wagle Ind. Estate Thane West, Mumbai – 400604.

Business Update

Bajaj Healthcare Limited (“BHL”) announces the receipt of the Establishment Inspection Report (EIR) from the United State Food and Drug Administration (USFDA), for the Pre-approval inspection that was carried out by the USFDA in November, 2022.

Thane, 13th September, 2023: Bajaj Healthcare Limited (BHL), a leading manufacturer of APIs, Intermediates and Formulations, has announced the receipt of the Establishment Inspection Report (EIR) from the United State Food and Drug Administration (USFDA), for the Pre-approval inspection that was carried out by the USFDA in November, 2022 at our API manufacturing facility in Savli, Vadodara, Gujarat.

BHL is pleased to inform that the Company has received the Establishment Inspection Report (EIR) from the USFDA for the Pre-Approval Inspection (PAI) at manufacturing site situated at Savli, Vadodara, Gujarat, with Zero 483 observations (No inspectional observations).

Commenting on the above business update, Mr. Anil Jain, Joint Managing Director, Bajaj Healthcare said: “In line with our previous communication to the exchanges in November 2022 regarding the successful completion of the first-ever pre-approval inspection carried out by the United States Food and Drug Administration (USFDA) at our API facility in Savli, Vadodara, Gujarat, I am pleased to inform you that the Company has now received the Establishment Inspection Report (EIR) from the USFDA for the Pre-Approval Inspection (PAI) conducted in November 2022.

The receipt of the Establishment Inspection Report (EIR) signifies the successful conclusion of the inspection. It serves as a testament to our dedication to upholding global standards of quality and compliance.

The receipt of the EIR also opens up the opportunities for filing companies own Drug Master Files with the USFDA as well as CDMO opportunities that company is eyeing with various customers across the globe.”

About Bajaj Healthcare Limited

Bajaj Healthcare Limited a leading manufacturer of APIs, Intermediates and Formulations established in the year 1993. It specializes in manufacturing of Intermediates, API, formulations & Nutraceuticals. The company has state-of-art manufacturing facilities, dedicated to APIs, Intermediates and formulation. These facilities are designed to meet the requirements of both advanced as well as emerging market opportunities. BHL has a strong presence globally in countries like Europe, USA, Australia, Africa, Middle East and South America.

For further information on the Company, please visit www.bajajhealth.com

Rupesh Nikam (CFO)

Bajaj Healthcare Limited

Contact: +91 22 6617 7400

Email: investors@bajajhealth.com

Disclaimer:

CERTAIN STATEMENTS IN THIS DOCUMENT MAY BE FORWARD LOOKING STATEMENTS. SUCH FORWARD-LOOKING STATEMENTS ARE SUBJECT TO CERTAIN RISKS AND UNCERTAINTIES LIKE GOVERNMENT ACTIONS, LOCAL POLITICAL OR ECONOMIC DEVELOPMENTS, TECHNOLOGICAL RISKS, AND MANY OTHER FACTORS THAT COULD CAUSE OUR ACTUAL RESULTS TO DIFFER MATERIALLY FROM THOSE CONTEMPLATED BY THE RELEVANT FORWARD-LOOKING STATEMENTS. BAJAJ HEALTHCARE LTD WILL NOT BE IN ANY WAY RESPONSIBLE FOR ANY ACTION TAKEN BASED ON SUCH STATEMENTS AND UNDERTAKES NO OBLIGATION TO PUBLICLY UPDATE THESE FORWARD-LOOKING STATEMENTS TO REFLECT SUBSEQUENT EVENTS OR CIRCUMSTANCE